PDF herunterladen
Thromb Haemost 2001; 85(05): 945-946
DOI: 10.1055/s-0037-1615779
Letters to the Editor
Schattauer GmbH

Avoiding Overanticoagulation: Pharmacogenomics or Pragmatism?

Trevor Baglin
1   Department of Haematology, Addenbrooke‘s Hospital, Cambridge University Hospitals Trust, Cambridge, UK
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 13. Dezember 2001

Accepted 25. Januar 2000

Publikationsdatum:
11. Dezember 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

 

 

  • References

  • 1 Margaglione M, Colaizzo D, D’Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-8.
    Thieme ConnectPubMedSuche in Google Scholar
  • 2 Mannucci P. Genetic control of anticoagulation. Lancet 1999; 353: 688-9.
    CrossrefPubMedSuche in Google Scholar
  • 3 Aithal G, Day C, Kesteven P, Daly A. Association of polymorphisms in the cytochrtome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
    CrossrefPubMedSuche in Google Scholar
  • 4 Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9.
    PubMedSuche in Google Scholar
  • 5 Panneerselvam S, Baglin C, Lefort W, Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol 1998; 103: 422-4.
    CrossrefPubMedSuche in Google Scholar
  • 6 Peters J, Luddington R, Brown K, Baglin C, Baglin T. Should patients starting anticoagulant therapy be screened for missense mutations at ALA-10 in the factor IX propeptide?. Br J Haematol 1997; 99: 467-8.
    PubMedSuche in Google Scholar